13F-HR filed by Aquilo Capital Management, LLC
Aquilo Capital Management, LLC filed this 13F-HR for the quarter ended 2021-03-31, filed 2021-05-17, with 17 holding rows worth $553,387,000.
- Accession
- 0001591986-21-000008
- Filer
- CIK 1591986
- Filed
- 2021-05-17
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q1 2021
A holdings report, 17 entries on the cover page, a total value of $553,387,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $553,387,000 with VALUE read as thousands by filing date, 13F file number 028-18892. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| SPY | 78462F103 | SHS | 300,000 | $118,899,000 | thousands by filing date | put |
| SPDR SER TR | 78464A870 | S&P BIOTECH | 500,000 | $67,825,000 | thousands by filing date | put |
| SPERO THERAPEUTICS INC | 84833T103 | COM | 3,829,209 | $56,366,000 | thousands by filing date | |
| DICERNA PHARMACEUTICALS INC | 253031108 | COM | 1,705,392 | $43,607,000 | thousands by filing date | |
| BLUEPRINT MEDICINES CORP | 09627Y109 | COM | 423,012 | $41,129,000 | thousands by filing date | |
| NGM BIOPHARMACEUTICALS INC | 62921N105 | COM | 1,124,237 | $32,682,000 | thousands by filing date | |
| HARPOON THERAPEUTICS INC | 41358P106 | COM | 1,554,199 | $32,514,000 | thousands by filing date | |
| UNIQURE NV | N90064101 | SHS | 955,424 | $32,188,000 | thousands by filing date | |
| DIANTHUS THERAPEUTICS INC COM | 55910K108 | Stock | 2,502,210 | $29,626,000 | thousands by filing date | |
| ARROWHEAD PHARMACEUTICALS IN | 04280A100 | COM | 407,926 | $27,050,000 | thousands by filing date | |
| REGENXBIO INC | 75901B107 | COM | 559,444 | $19,083,000 | thousands by filing date | |
| 4D MOLECULAR THERAPEUTICS INC COM | 35104E100 | Stock | 300,886 | $13,052,000 | thousands by filing date | |
| AMRYT PHARMA LTD - SPNR ADR | 03217L106 | COMMON EQUITY | 800,000 | $11,144,000 | thousands by filing date | |
| PIERIS PHARMACEUTICALS INC | 720795103 | COM | 3,675,530 | $9,446,000 | thousands by filing date | |
| LAKEFRONT BIOTHERAPEUTICS NV | 36315X101 | SPON ADR | 116,723 | $8,998,000 | thousands by filing date | |
| ARGENX SE SPONSORED ADR | 04016X101 | ADR | 21,200 | $5,838,000 | thousands by filing date | |
| GENMAB A/S | 372303206 | Ordinary Shares, nominal value DKK 1 per share | 120,000 | $3,940,000 | thousands by filing date |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001591986-21-000008 | this filing | 2021-05-17 | acceptance time not in the bulk data set |